Latest & greatest articles for ciprofloxacin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ciprofloxacin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ciprofloxacin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ciprofloxacin

21. A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh

A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh Article Text Therapeutics A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2006

22. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial.

Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. 16182896 2005 09 26 2005 10 12 2016 06 21 1474-547X 366 9491 2005 Sep 24-30 Lancet (London, England) Lancet Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. 1085-93 Single-dose ciprofloxacin is effective for the treatment of severe cholera in adults. We assessed whether single-dose ciprofloxacin would be as effective as 3-day, 12 (...) -dose erythromycin in achieving clinical cure in children with severe cholera. We did a randomised, open label, controlled trial in children age 2-15 years with V cholerae O1 or O139 present in stool on dark-field microscopy. Children received either a single 20 mg/kg dose of ciprofloxacin (n=90) or 12.5 mg/kg of erythromycin (n=90) every 6 h for 3 days, and remained in hospital for 5 days. The primary outcome was clinical success of treatment, defined as cessation of watery stools within 48 h

Lancet2005

23. ciprofloxacin hydrochloride and dexamethasone otic suspension

ciprofloxacin hydrochloride and dexamethasone otic suspension Common Drug Review CEDAC Meeting—November 17, 2004; CEDAC Reconsideration – January 19, 2005 Page 1 of 1 Notice of CEDAC Final Recommendation on Reconsideration – January 26, 2005 CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION CIPROFLOXACIN HCL and DEXAMETHASONE OTIC SUSPENSION (Ciprodex® – Alcon Canada Inc.) Ciprodex® is a combination of ciprofloxacin HCl and dexamethasone that is indicated (...) for the local treatment of acute otitis media with otorrhea through tympanostomy tubes in pediatric patients aged six months and older and for acute otitis externa in pediatric and adult patients aged one year and older. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that ciprofloxacin HCl/ dexamethasone otic suspension not be listed. Reasons for the recommendation: 1. For patients with otitis externa, one randomized trial of relatively poor quality (allocation concealment

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2005

24. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial.

Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. 15728165 2005 02 24 2005 03 01 2016 10 19 1538-3598 293 8 2005 Feb 23 JAMA JAMA Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. 949-55 The high prevalence of resistance to trimethoprim-sulfamethoxazole and other antimicrobials among Escherichia coli causing acute cystitis in women has led to increased use (...) of alternative antibiotics. One such antibiotic, amoxicillin-clavulanate, has not been well studied. To compare the efficacy of a 3-day regimen of amoxicillin-clavulanate to that of a 3-day regimen of ciprofloxacin in the treatment of acute cystitis in women. The primary study hypothesis was that the amoxicillin-clavulanate and ciprofloxacin treatment groups would differ in clinical cure. Randomized, single-blind treatment trial of 370 women, aged 18 to 45 years, with symptoms of acute uncomplicated cystitis

JAMA2005

25. Isolation of Salmonella enterica serotype choleraesuis resistant to ceftriaxone and ciprofloxacin.

Isolation of Salmonella enterica serotype choleraesuis resistant to ceftriaxone and ciprofloxacin. Salmonella enterica serotype choleraesuis (S choleraesuis) usually causes systemic infections in man that need antimicrobial treatment. We isolated a strain of S choleraesuis that was resistant to ceftriaxone and ciprofloxacin from a patient with sepsis. Ciprofloxacin resistance was associated with mutations in gyrA and parC, whereas the ampC gene (bla(CMY-2)), responsible for ceftriaxone

Lancet2004

26. Cipro (Ciprofloxacin Hydrochloride) Tablets, Cipro IV (Ciprofloxacin) Solution, Cipro (Ciprofloxacin) Oral Suspension

Cipro (Ciprofloxacin Hydrochloride) Tablets, Cipro IV (Ciprofloxacin) Solution, Cipro (Ciprofloxacin) Oral Suspension Drug Approval Package: Cipro (Ciprofloxacin Hydrochloride) Tablets, Cipro IV (Ciprofloxacin) Solution, Cipro (Ciprofloxacin NDA #019537s049, 019847s027, 019857s031 & 020780s013 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Cipro (Ciprofloxacin Hydrochloride) Tablets, Cipro IV (Ciprofloxacin) Solution, Cipro (Ciprofloxacin) Oral

FDA - Drug Approval Package2004

27. Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002.

Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) monitors trends in antimicrobial resistance in consecutive gonococcal isolates from 26 genitourinary medicine clinics in England and Wales. In 2002, 2204 gonococcal isolates were tested, and the overall prevalence of ciprofloxacin resistance (minimum inhibitory concentration > or =1 mg/L) was 9.8%, compared with 3.1% in 2001 and 2.1 (...) % in 2000. Between 2001 and 2002, prevalence of ciprofloxacin resistance increased two to three-fold, irrespective of recent sexual contact overseas, sex, or residence within or outside of London. These findings suggest that national and local treatment guidelines need to be reviewed urgently.

Lancet2003

28. Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis

Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis Tuncer I, Topcu N, Durmus A, Turkdogan M K Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Cirrhotic patients with spontaneous bacterial peritonitis (SBP) were given 500 mg ciprofloxacin (Cipro; Biofarma) orally, every 12 hours for 5 days (group A). The comparators were 2 g intravenous cefotaxime (Sefotak; Eczacibasi) given every 8 hours for 5 days (group B), and 2 g

NHS Economic Evaluation Database.2003

29. Cipro XR (Ciprofloxacin) Extended-Release Tablets

Cipro XR (Ciprofloxacin) Extended-Release Tablets Drug Approval Package: Cipro XR (Ciprofloxacin) NDA #021554 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Cipro XR (Ciprofloxacin) Extended-Release Tablets Company: Bayer Pharmaceuticals Corporation Application No.: 021554 Approval Date: 8/28/2003 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: December 012005 Note: Documents in PDF format require the . - - Links on this page: Note

FDA - Drug Approval Package2003

30. Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis

Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis Kurzer E, Kaplan S A Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two antibiotics for the treatment of chronic bacterial prostatitis (CBP) were studied. These were trimethoprim-sulfamethoxazole (TMP-SMX) and ciprofloxacin. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population

NHS Economic Evaluation Database.2002

31. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial.

Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. 10735395 2000 04 04 2000 04 04 2016 10 17 0098-7484 283 12 2000 Mar 22-29 JAMA JAMA Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. 1583-90 The optimal antimicrobial regimen and treatment duration for acute (...) uncomplicated pyelonephritis are unknown. To compare the efficacy and safety of a 7-day ciprofloxacin regimen and a 14-day trimethoprim-sulfamethoxazole regimen for the treatment of acute pyelonephritis in women. Randomized, double-blind comparative trial conducted from October 1994 through January 1997. Twenty-five outpatient centers in the United States. Of 378 enrolled premenopausal women aged at least 18 years with clinical diagnosis of acute uncomplicated pyelonephritis, 255 were included

JAMA2000

32. A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis

A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis Marra C A, Frighetto L, Quaia C B, de Lemos M L, Warkentin D I, Marra F, Jewesson P J Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Adult patients with febrile neutropenia in a leukaemia stem-cell transplant unit were given an antibiotic regimen that, in part, involved reducing the dose of intravenous (i.v.) ciprofloxacin from 400 to 200 mg every 12 hours before

NHS Economic Evaluation Database.2000

33. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalised patients with severe pneumonia

Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalised patients with severe pneumonia Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalised patients with severe pneumonia Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalised patients with severe pneumonia Caldwell J W, Singh (...) S, Johnson R H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of intravenous ciprofloxacin or imipenem therapy in the treatment of hospitalised patients with severe pneumonia. Type of intervention Treatment. Economic study

NHS Economic Evaluation Database.1999

34. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections

Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections Walters D J, Solomkin J S, Paladino J A Record Status This is a critical abstract of an economic evaluation (...) the relative robustness of the favourable results to a switch from IV to oral therapy. Authors' conclusions In patients able to receive oral therapy, sequential IV to oral treatment with ciprofloxacin plus metronidazole was cost-effective compared with full IV courses of ciprofloxacin plus metronidazole or imipenem-cilastatin. In patients unable to receive oral therapy, no difference in mean cost was found between IV imipenem-cilastatin or IV ciprofloxacin plus IV metronidazole. CRD COMMENTARY - Selection

NHS Economic Evaluation Database.1999

35. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year

Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients (...) followed for 1 year Torrance G, Walker V, Grossman R, Mukherjee J, Vaughan D, La Forge J, Lampron N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of ciprofloxacin for the treatment of acute exacerbations of chronic bronchitis

NHS Economic Evaluation Database.1999

36. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B

Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients (...) : no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B Schroder C P, de Vries E G, Mulder N H, Willemse P H, Sleijfer D T, Hospers G A, van der Graaf W T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions

NHS Economic Evaluation Database.1999

37. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy

Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy Kapoor D A, Klimberg I W, Malek G H, Wegenke J D, Cox C E, Patterson A L, Graham E, Echols R M, Whalen E, Kowalsky S F Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Antimicrobial prophylaxis (a single oral 500-mg dose of ciprofloxacin administered before the diagnostic procedure) in the prevention of infections in patients undergoing transrectal needle biopsy of the prostate. Type of intervention Primary prevention. Economic study

NHS Economic Evaluation Database.1998

38. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute (...) exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group Grossman R, Mukherjee J, Vaughan D, Eastwood C, Cook R, LaForge J, Lampron N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use

NHS Economic Evaluation Database.1998

39. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis.

Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. 9716056 1998 09 08 1998 09 08 2015 06 16 0140-6736 352 9127 1998 Aug 15 Lancet (London, England) Lancet Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. 522-7 Infections caused by multiply resistant Shigella species are a major cause of childhood morbidity and mortality in Third World countries. The fluoroquinolone agent ciprofloxacin is active in vitro (...) against these strains of bacteria, but has not been routinely used to treat acute childhood infections because of concern that quinolones may cause arthropathy in children. We undertook a randomised double-blind study to test the effects of ciprofloxacin treatment in children with shigella dysentery. We compared the efficacy and toxic effects of ciprofloxacin suspension (10 mg/kg every 12 h for 5 days, maximum individual dose 500 mg) with those of pivmecillinam tablets (15-20 mg/kg every 8 h for 5

Lancet1998

40. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis

Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis Amodio-Groton M, Madu A, Madu C N, Briceland L L, Seligman M, McMaster P, Miller M H Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Initial intravenous antibiotic regimen followed by oral ciprofloxacin (a broad-spectrum fluoroquinolone antimicrobial) in the treatment of patients with gram negative bacteremia. Type of intervention Treatment. Economic study type

NHS Economic Evaluation Database.1996